The Chemours Company (NYSE:CC) Stock Position Cut by Khrom Capital Management LLC

Khrom Capital Management LLC cut its holdings in The Chemours Company (NYSE:CC - Free Report) by 34.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,183,351 shares of the specialty chemicals company's stock after selling 1,159,331 shares during the quarter. Chemours accounts for 4.2% of Khrom Capital Management LLC's investment portfolio, making the stock its 10th largest position. Khrom Capital Management LLC owned about 1.46% of Chemours worth $36,899,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in CC. Vanguard Group Inc. increased its stake in Chemours by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 15,223,961 shares of the specialty chemicals company's stock worth $257,285,000 after buying an additional 94,885 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Chemours by 1.2% during the third quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company's stock worth $50,646,000 after purchasing an additional 28,803 shares in the last quarter. Norges Bank acquired a new position in Chemours in the 4th quarter valued at $30,702,000. Dimensional Fund Advisors LP lifted its holdings in Chemours by 22.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,779,702 shares of the specialty chemicals company's stock valued at $30,077,000 after purchasing an additional 328,414 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Chemours by 7.6% during the 4th quarter. American Century Companies Inc. now owns 1,625,019 shares of the specialty chemicals company's stock worth $27,463,000 after purchasing an additional 115,436 shares during the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Trading Down 0.6 %

CC stock traded down $0.08 during midday trading on Friday, hitting $12.36. 1,658,033 shares of the company's stock were exchanged, compared to its average volume of 1,864,138. The Chemours Company has a 1-year low of $9.33 and a 1-year high of $29.21. The business has a 50-day simple moving average of $13.30 and a two-hundred day simple moving average of $17.07. The stock has a market capitalization of $1.85 billion, a PE ratio of 21.68 and a beta of 1.84. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. On average, sell-side analysts predict that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were issued a $0.25 dividend. The ex-dividend date was Friday, February 28th. This represents a $1.00 annualized dividend and a dividend yield of 8.09%. Chemours's dividend payout ratio is currently 175.44%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Truist Financial reduced their target price on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Barclays decreased their target price on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 1st. Morgan Stanley dropped their price target on Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. The Goldman Sachs Group lowered their price objective on Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 7th. Finally, Mizuho set a $15.00 target price on Chemours in a report on Tuesday, April 15th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $21.56.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.